J Biol Chem, Vol. 275, Issue 16, 11921-11928, April 21, 2000
Protein Kinase C-
and Oxygen Deprivation
A NOVEL Egr-1-DEPENDENT PATHWAY FOR FIBRIN DEPOSITION IN
HYPOXEMIC VASCULATURE*
Shi-Fang
Yan
§,
Jiesheng
Lu
,
Yu Shan
Zou
,
Walter
Kisiel¶,
Nigel
Mackman
,
Michael
Leitges**,
Susan
Steinberg
,
David
Pinsky
, and
David
Stern
From the
Departments of Surgery, Physiology & Cellular Biophysics, Pharmacology and Medicine, College of
Physicians and Surgeons of Columbia University, New York, New York
10032, the ¶ Department of Pathology, University of New Mexico
School of Medicine, Albuquerque, New Mexico 87131, the
Department of Immunology and Vascular Biology, Scripps Research
Institute, La Jolla, California 92037, and the ** Molecular
Embryology Unit, Max Planck Institute for Immunobiology,
79108 Freiburg, Germany
 |
ABSTRACT |
Fibrin deposition is a salient feature of
hypoxemic vasculature and results from induction of tissue factor. Such
tissue factor expression in an oxygen deficient environment is driven
by the transcription factor Early Growth Response (Egr)-1. Using
homozygous null mice for the protein kinase C
-isoform gene (PKC
null), PKC
is shown to be upstream of Egr-1 in this oxygen
deprivation-mediated pathway for triggering procoagulant events.
Whereas wild-type mice exposed to hypoxia (6%) displayed a robust
increase in tissue factor transcripts and antigen, and vascular fibrin
deposition, PKC
null animals showed a markedly blunted response.
Consistent with a central role for Egr-1 in hypoxia-induced expression
of tissue factor, PKC
null mice subjected to oxygen deprivation displayed at most a minor elevation in Egr-1 transcripts, antigen, and
intensity of the gel shift band by electrophoretic mobility shift
assay, compared with normoxic animals. These data firmly establish
PKC
as a trigger for events leading to induction of Egr-1 and tissue
factor under hypoxic conditions, and provide insight into a biologic
cascade whereby oxygen deprivation recruits targets of PKC
and
Egr-1, thereby amplifying the cellular response.
 |
INTRODUCTION |
Oxygen deprivation is a frequently encountered physiologic stress
accompanying disorders of the lung and cardiovascular system, as well
as consequent to high altitude exposure. The cellular response to
hypoxia is complex and involves a range of mechanisms, some occurring
within minutes of oxygen deprivation, whereas others reset multistep
biosynthetic and physiologic programs (1-9). For example,
hypoxia-induced translocation of P-selectin to the endothelial cell
surface, thereby promoting adherence of leukocytes at sites of ischemic
stress, occurs within minutes and is due to a transient rise in
cytosolic calcium (4). The best characterized mechanism triggering
biosynthetic adaptation to oxygen deprivation involves the
transcriptional regulator hypoxia-inducible factor-1 (HIF-1)1 (2, 3, 10).
Activation of HIF-1 at low ambient oxygen tension results in expression
of an array of genes, which, in a highly integrated manner, redirects
metabolic and other cellular mechanisms enhancing cell survival in the
hypoxic environment (2, 3, 7, 10). HIF-1 increases expression of the
noninsulin-dependent glucose transporter (GLUT1) (11) and
multiple glycolytic enzymes (12), thereby promoting glucose uptake and
glycolysis, as the efficacy of aerobic respiration is diminished due to
limited oxygen availability. In a highly complementary manner,
increased levels of erythropoietin and vascular endothelial growth
factor expand oxygen carrying capacity of the blood and, over time,
enhance ingrowth of vessels to sites of hypoxemia, respectively (2, 3,
13). The positive impact of these changes for cellular and organ
homeostasis is evident from the lethal phenotype of homozygous null
mice for either vascular endothelial growth factor or HIF-1
(14-17).
Another facet of the biosynthetic response to hypoxia concerns
expression of oxygen-regulated proteins (ORPs), which occurs within the
first 48 h of hypoxia (8). The ORPs comprise a group of
polypeptides whose members overlap with glucose-regulated proteins (GRPs), such as GRP78 and GRP94 (18), well known for their role as
chaperones in the endoplasmic reticulum (ER). Studies of ORP150, a
recently described member of this group cloned from hypoxic astrocytes
(19), also places it in the ER; enhanced expression of ORP150 in
response to severe oxygen deprivation promotes cell survival (20).
These data indicate that ER stress, likely due to accumulation of
incompletely folded/misfolded proteins in the ER, as energy depletion
and changes in protein biosynthesis impair normal protein processing,
is an important feature of the intracellular milieu in hypoxia.
Our recent studies have highlighted a quite distinct pathway triggered
by oxygen deprivation. Hypoxia causes transcriptional activation of
tissue factor, the key procoagulant cofactor that initiates the
coagulation mechanism resulting, ultimately, in vascular fibrin
formation (6, 21, 22). Increased tissue factor in hypoxemic vasculature
is especially evident in mononuclear phagocytes (MPs) (6, 21). Further
analysis of this pathway showed that induction of tissue factor
expression resulted from up-regulation of the transcription factor
Early Growth Response (Egr)-1 (22). For example, homozygous Egr-1 null
mice subjected to hypoxia did not display either enhanced tissue factor
expression or vascular fibrin deposition. As fibrin accumulation in
vessels subject to hypoxemia could have far-reaching pathophysiological consequences (23, 24) and increased levels of Egr-1 could recruit
multiple other target genes, we have performed further studies to
elucidate mechanisms underlying transcriptional activation of Egr-1 in
response to oxygen deprivation. Our first studies using cultured cell
lines suggested that events leading to Egr-1 expression could be traced
back to protein kinase C isoform
II (PKC
II) (22). Because of the
complex array of PKC isoforms and their overlapping properties, as well
as the likelihood that results in established cell lines subject to
transient transfection with multiple expression constructs would not
faithfully model all aspects of the in vivo milieu, we have
turned to experiments in genetically manipulated mice. In this regard,
mice deficient in the PKC
gene (since PKC
I and PKC
II isoforms
are encoded by the same gene, these mice are deficient in both) have
been produced by homologous recombination (termed PKC
null mice)
(25). The phenotype of these animals includes immunologic
abnormalities, impaired humoral immune responses and reduced cellular
responses to B cells, similar to those observed in X-linked
immunodeficiency, although survival, reproductive status, and other
general properties of these mice appear to be intact. Using PKC
null
animals, we have established a central role for PKC
in the pathway
triggered by hypoxia leading to activation of Egr-1 and tissue factor
expression, and resulting in fibrin deposition in lung vasculature.
These studies delineate a new facet of the response to oxygen
deprivation, distinct from HIF-1, which is likely to initiate a complex
pattern of biosynthetic changes in hypoxic/hypoxemic environments.
 |
EXPERIMENTAL METHODS |
Induction of Hypoxia in Vivo and in Vitro--
Experiments
employing mice subjected to hypoxia were performed according to
protocols approved by the Institutional Animal Care and Use Committee
at Columbia University, in accordance with the Association for the
Accreditation of Laboratory Animal Care guidelines. Homozygous PKC
null mice were prepared as described (25). Both PKC
null and
wild-type controls (12-15 weeks old) were in a similar mixed
background (129xC57BL6). However, since the 129 strain actually
comprises a collection of genetically heterogeneous substrains, it is
more than likely that the control mice (which were most likely derived
from a different strain wild-type embryonic stem cell than the PKC
null mice) are not genetically identical to the knockout mice. Mice
were subjected to normobaric hypoxia (n = 5 per
experimental condition unless indicated otherwise) for the indicated
times by the regulated addition of nitrogen to a chamber equipped with
circulating fans, carbon dioxide and ammonia elimination systems, and
an on-line oxygen sensor (Horiba Ltd., Kyoto, Japan) (6). The
environment within the chamber (including temperature and humidity) was
regulated by a custom-built interface (K+K Interface Inc.,
New York, NY), which used a computer-driven environmental control
program. Mice placed in the chamber in their usual cages were allowed
free access to food and water, and the system parameters were adjusted
to a final oxygen concentration of 5.5-6.5%. Mice exposed to hypoxia
were tachypneic and had reduced activity, compared with normoxic
counterparts, but there was no mortality during the experimental
period. At the indicated times, animals were sacrificed, and tissues
were studied as described below.
Cells were subjected to hypoxia using an environmental chamber (Coy
Laboratory Products, Ann Arbor, MI), which maintained a controlled
temperature (37 °C), an humidified atmosphere with carbon dioxide
(5%) and the balance made up of nitrogen. Use of this chamber for
cultured cells has been described previously (6). The pH of the medium
remained unchanged throughout experiments; pO2 in the
medium was
12-14 torr (oxygen leached continuously from the tissue
culture plasticware during the course of the experiments). The glucose
concentration fell by less than 10-20% during the longest
experimental time points (4 h; this degree of glucose depletion does
not induce changes in gene expression described below). Exposure of
cultured MPs to hypoxia (see below) did not alter cell viability, as
assessed by: (i) lack of increased release of intracellular markers,
such as lactate dehydrogenase; (ii) continued exclusion of trypan blue;
(iii) continued protein synthesis (see below); and (iv) continued cell
adherence to the substrate. Cells subjected to hypoxia were exposed to
medium pre-equilibrated with the hypoxic gas mixture just prior to
placement in the environmental chamber. Thus, cultures were immediately
immersed in the oxygen-deprived environment at the time of medium
change/placement in the chamber.
Analysis of Egr-1, ERK1/2, Tissue Factor, Fibrin, and GLUT1 in
Genetically Manipulated Mice--
Following hypoxia, mice were
sacrificed and tissue was processed immediately. For Northern analysis,
tissue was cut into small pieces, immersed in Trizol (Life
Technologies, Inc.), and homogenized, and total RNA was extracted and
subjected to electrophoresis (0.8% agarose). RNA was transferred to
Duralon-UV membranes (Stratagene), and membranes were then hybridized
with 32P-labeled cDNA probe for mouse Egr-1 (26),
tissue factor (6), or GLUT1 (27). Blots were also hybridized with
32P-labeled
-actin as an internal control for RNA loading.
For Western blotting of Egr-1, nuclear extracts were prepared (see
below), and subjected to SDS-PAGE (7.5%; nonreduced). Proteins in the
gel were transferred electrophoretically to nitrocellulose membranes,
and immunoblotting was performed with rabbit anti-Egr-1 IgG (Santa Cruz
Biotechnology) according to the Blotto procedure (28). Sites of primary
antibody binding were visualized with horseradish peroxidase-conjugated
goat anti-rabbit IgG (Amersham International, Buckinghamshire, United
Kingdom). Final detection of immunoreactive bands was performed using
the enhanced chemiluminescent Western blotting system (Amersham). A
similar strategy was utilized to detect ERK1/2, except that an extract
of total cell protein was employed, and anti-MAPK IgG (reactive with
ERK1/2 regardless of phosphorylation status; Zymed
Laboratories Inc.) or anti-active MAPK IgG (1:5000 dilution; the
latter selective for phosphorylated ERK1/2; Promega) was used as the
primary antibody (29, 30).
For immunoblotting of tissue samples for fibrin, lung was harvested
from animals treated with heparin (10 units/g, resulting in an
activated partial thromboplastin time >300 s) prior to sacrifice (21).
Tissue was placed in buffer (0.05 M Tris, 0.15 M NaCl, 500 units/ml heparin; final pH 7.6) on ice and
homogenized. Plasmin digestion was performed by a modification of the
method of Francis (31) by adding human plasmin (0.32 units/ml, Sigma)
and incubating the sample for 6 h at 37 °C. This was followed
by addition of more plasmin (0.32 units/ml) and additional incubation
for 2 h, followed by centrifugation (2,300 × g
for 15 min), and aspiration of the supernatant. Samples of
plasmin-treated hypoxic and normoxic lung homogenates (200 µg of
total protein) were boiled in reducing SDS-sample buffer for 5 min and
subjected to SDS-PAGE (10%; reduced). Samples were electrophoretically
transferred to nitrocellulose, and blots were reacted with rabbit
anti-fibrin antibody made to
-
chain cross-links (21, 32),
followed by affinity-purified peroxidase-conjugated anti-rabbit IgG
(Sigma). Final detection of the bands was as above.
For immunocytochemical studies, lung tissue was harvested, cut into
small pieces, washed with phosphate-buffered saline (pH 7.0) to remove
blood, fixed in formalin, and embedded in paraffin (6, 22). Sections
were first stained with primary antibodies, rabbit anti-Egr-1 IgG (8 µg/ml; Santa Cruz), rat F4/80 monoclonal antibody (10 µg/ml; Caltag
Laboratories, South San Francisco, CA), rabbit anti-tissue factor IgG
(63 µg/ml) (21), rabbit anti-phosphorylated ERK1/2 (1:500 dilution;
New England Biolabs, Beverly, MA), or rabbit anti-fibrin antibody (4 µg/ml). Then, they were incubated with secondary antibody, an
affinity-purified peroxidase-conjugated anti-rabbit or anti-rat IgG (Sigma).
The electrophoretic mobility gel shift assay was performed on nuclear
extracts prepared immediately after harvest of the hypoxic lung by the
method of Dignam et al. (33). Double-stranded
oligonucleotide probes for Egr (Santa Cruz Biotechnology) were 5'
end-labeled with [32P]ATP (3,000 Ci/mmol) using T4
polynucleotide kinase and standard procedures. Binding reactions were
performed as described (34), and samples (5 µg of protein in each
lane) were loaded directly onto nondenaturing
polyacrylamide/bisacrylamide (6%) gels prepared in 0.5× TBE (45 mM Tris, 45 mM boric acid, 1 mM
EDTA). Gels were pre-run for 20 min before samples were loaded, and
electrophoresis was performed at room temperature for 1.5-2 h at 200 V. For competition studies, an 100-fold molar excess of unlabeled
probes for either Egr (Santa Cruz Biotechnology) or Sp1 (Promega) was added.
Studies with Cultured MPs--
Resident peritoneal MPs were
harvested from PKC
null and wild-type mice by lavage with ice-cold
medium (35). Cells were maintained in culture in complete medium (RPMI
1640 with fetal calf serum (10%)) for 24 h and then serum-starved
for the next 24 h prior to placement in the hypoxic environment.
Then, cultured MPs were subjected to hypoxia for 4 h or were
exposed to lipopolysaccharide (LPS; 1 µg/ml; Escherichia
coli serotype 026B6; Sigma) for 6 h or to phorbol
12-myristate 13-acetate (50 ng/ml; Sigma) for 1 h. RT-PCR for
tissue factor transcripts was performed using the following
primers: 5' -TTGATGTGGAAGAAGGAGTA-3' (sense) and
5'-TGGAATCAAAGCGTTAGC-3' (antisense). The size of the amplified
DNA fragment was 416 base pairs, and it was also identified by Southern
blotting with a 32P-labeled fragment from the murine
cDNA for tissue factor (322 base pairs), which did not contain the
region included in the tissue factor primers. Other experiments were
performed with a line of rat alveolar macrophages (NR8383) obtained
from ATCC (Manassas, VA) and grown in Ham's F12K containing 15%
heat-inactivated fetal calf serum. NR8383 cells were incubated with the
specific PKC
inhibitor LY379196 (36, 37) alone, or in the presence
of LPS or an hypoxic environment. Total RNA was isolated and either
subjected to Northern analysis using 32P-labeled cDNA
probes for Egr-1, GLUT1, or
-actin. Where indicated, autoradiograms
were scanned with a Hewlett-Packard ScanJet IICX linked to a Macintosh
G3 computer, and images were quantitated and compared using Molecular
Analyst software (Bio-Rad).
 |
RESULTS |
Expression of Egr-1 and Activation of ERK1/2 in Hypoxic Lung:
Effect of PKC
Deletion--
In a previous study, hypoxia was shown
to induce Egr-1 expression and Egr-1-dependent
transcription of tissue factor (22). In order to assess whether PKC
might participate in upstream events leading to Egr-1 up-regulation,
PKC
null mice were subjected to oxygen deprivation and Egr-1
expression was compared with that observed in age- and strain-matched
controls. Wild-type mice demonstrated strong up-regulation of
transcripts for Egr-1 mRNA in the lung within 30 min of exposure to
the environment with 6% oxygen (Fig. 1A, lanes
1 and 2;
16-fold increase in intensity of the
band in samples from hypoxic lung compared with normoxic controls). In
contrast, PKC
null mice subjected to hypoxia for the same time
showed only a weak increase in Egr-1 transcripts (Fig.
1A, lanes
3 and 4;
1.6-fold increase in hypoxia compared
with normoxia). Immunoblotting of nuclear extracts from hypoxic lung
confirmed that increased amounts of Egr-1 antigen were present in
samples from wild-type mice after 30 min, compared with normoxic
controls (Fig. 1B, lanes 1 and
2). In fact, the rapidity of the rise in Egr-1 antigen
suggests that even post-translational mechanisms related to protein
stabilization might also be involved. Analogous to the lower levels of
Egr-1 mRNA in PKC
null mice, the knockouts showed an
immunoreactive band of low intensity after exposure to hypoxia (Fig.
1B, lanes 3 and 4),
versus the robust response in wild-type mice. In hypoxic
lung from wild-type mice, Egr-1 antigen was especially evident in
smooth muscle cells and in mononuclear phagocytes (Fig. 1D;
panel C shows Egr-1 immunostaining in the normoxic control). Staining of adjacent sections with F4/80
demonstrated colocalization of this murine monocyte marker (Fig.
1F) in cells expressing Egr-1 (Fig. 1E). The
PKC
null mice showed only low levels of Egr-1 antigen in lungs of
normoxic and hypoxic mice (Fig. 1, G and H). Gel
shift analysis of nuclear extracts from lungs of wild-type mice using
32P-labeled consensus oligonucleotide probe for Egr
demonstrated a gel shift band whose intensity increased strongly in
response to hypoxia (Fig. 1I, lanes 2 and 3). Nuclear binding activity was sequence-specific,
based on competition with excess unlabeled Egr probe, but not unlabeled
oligonucleotide probe for Sp1 (data not shown). When PKC
null mice
were exposed to hypoxia, the intensity of the gel shift band from
nuclear extracts of lung increased minimally compared with normoxia
(Fig. 1I, lanes 4 and 5).
These data demonstrate that deletion of the PKC
gene strongly
inhibits signaling events in the lung leading to induction of Egr-1.
The small residual increase in Egr-1 in PKC
null mice was not
reproducible (often being similar to normoxic controls) and, thus, was
difficult to characterize further.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 1.
Hypoxia-mediated induction of Egr-1 and Egr-1
DNA binding activity in hypoxic murine lung: effect of
PKC deletion. A, wild-type
(+/+) and PKC null ( / ) mice were exposed to hypoxia
(H; 6% oxygen) or normoxia (N) for 30 min,
sacrificed, and total RNA was isolated from the lung, and subjected to
Northern analysis (10 µg/lane) with 32P-labeled cDNA
probes for Egr-1 and -actin. B, immunoblotting with
anti-Egr-1 IgG was performed on nuclear extracts from lungs of mice
exposed to hypoxia (H) or normoxia (N) for 30 min. Each lane was loaded with 10 µg of total protein.
C-H, immunostaining for Egr-1 in lungs of normoxic
(C) or hypoxic (D) wild-type mice. Adjacent
sections of lung from wild-type animals exposed to hypoxia were stained
with antibody to Egr-1 (E) and F4/80 (F).
Panels G and H show immunostaining for
Egr-1 in lungs from normoxic (G) and hypoxic (H)
PKC null mice. In C, D, G, and
H, marker bar = 5 µm. In
E and F, marker bar = 2 µm. The arrows in E and F point to
the same areas/cells in adjacent sections. I,
electrophoretic mobility gel shift assay with 32P-labeled
consensus Egr oligonucleotide probe and nuclear extracts from lungs of
wild-type or PKC null mice exposed to hypoxia or normoxia (5 µg/lane). FP indicates a lane with only free probe.
|
|
In a cultured monocyte-like cell line, we had observed previously that
hypoxia caused translocation of PKC
II to the membranous fraction and
autophosphorylation, and closely correlated with events leading to
Egr-1 expression by a pathway that involved activation of MAP kinases
ERK1/2 (22). This led us to examine whether activation of ERK1/2
occurred in hypoxic lung, and if this would be altered in PKC
null
mice. Wild-type mice were exposed to hypoxia for 10 min, and lung
homogenates were prepared for immunoblotting with antibody specific for
phosphorylated ERK1/2 (29, 30). A strong increase in intensity of
immunoreactive material with mass
42/44 kDa, corresponding to the
migration of phospho-ERK1/2, was observed in hypoxic, versus
normoxic, samples (Fig. 2A, lanes 2 and
1, respectively). Similar experiments performed with lung
homogenates from PKC
null mice showed only low levels of
phosphorylated ERK1/2 antigen in normoxic and hypoxic mice (Fig.
2A, lanes
3 and 4). The latter result was obtained after 10 min of hypoxia (a time point when strong ERK1/2 activation was observed
in wild-type mice); experiments performed at shorter and longer
incubation times using PKC
null mice did not show increased
phospho-ERK1/2, indicating the apparent absence of ERK1/2 activation,
rather than just an altered time course (data not shown).
Panel B displays the presence of similar levels
of total ERK1/2 antigen in lung harvested from wild-type and PKC
null mice under normoxic and hypoxic conditions. Immunostaining was performed on lung tissue from normoxic and hypoxic mice with antibody to phosphorylated ERK1/2. Compared with normoxic controls (Fig. 2C), immunoreactive material was found lungs of wild-type
hypoxic mice (Fig. 2D) in a distribution corresponding to
vascular smooth muscle cells (main panel in
D) and mononuclear phagocytes (inset to
D). Studies on lung tissue from PKC
null animals
demonstrated little immunoreactivity in lungs from either normoxic and
hypoxic animals (Fig. 2, E and F). Thus, deletion
of PKC
prevents an hypoxia-mediated signaling pathway in which
ERK1/2 activation/phosphorylation is tied to up-regulation of
Egr-1.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 2.
Hypoxia-mediated activation of ERK1/2 in
hypoxic murine lung: effect of PKC
deletion. A and B, wild-type (+/+) and
PKC null ( / ) mice were exposed to hypoxia (H; 6%
oxygen) or normoxia (N) for 10 min, sacrificed, and protein
extracts from the lung were prepared and subjected to SDS-PAGE (10%;
50 µg of protein/lane)/immunoblotting with anti-active MAPK IgG
(A) or anti-MAPK IgG (B; this antibody detects
all ERK1/2 regardless of activation state). C-F,
immunostaining using antibody to phosphorylated ERK1/2 in lungs from
normoxic (C) or hypoxic (D) wild-type mice.
Panels E and F show immunostaining for
activated ERK1/2 in normoxic (E) and hypoxic (F)
PKC null mice. In C-F, marker
bar = 5 µm. In the inset to
panel D, marker bar = 1 µm.
|
|
Expression of Tissue Factor and Induction of Fibrin Formation in
Hypoxic Lung: Effect of PKC
Deletion--
Wild-type mice exposed to
hypoxia display activation of Egr-1, which, in turn, triggers increased
transcription of the tissue factor gene (6). Thus, wild-type mice
subjected to oxygen deprivation showed elevated levels of steady-state
tissue factor mRNA (Fig. 3A, lane
2;
20-fold increase comparing lanes
2 and 1), which was followed by enhanced
expression of tissue factor antigen in the lung (Fig. 3C),
versus normoxic controls (Fig.
3B). Further studies showed
the distribution of tissue factor antigen in lungs from oxygen-deprived
animals to overlap that observed for hypoxia-induced Egr-1 expression
and activated ERK1/2, being found principally in smooth muscle cells
and MPs (data not shown). When the same protocol was followed with
PKC
null mice, animals subjected to hypoxia showed only a slight
increase in tissue factor transcripts on Northern blots (Fig.
3A, lane 4;
2.2-fold increase
comparing lanes 3 and 4) and virtually
no elevation of immunoreactive tissue factor in the lung (Fig.
3E), compared with PKC
null mice maintained in normoxia
(Figs. 3, A, lane 3, and
D). As with levels of Egr-1 in hypoxic PKC
null mice, the
residual increase in tissue factor was variable and at extremely low
levels, making it difficult to analyze in detail. The key role of
tissue factor in fibrin deposition in hypoxic lung was displayed by
immunoblotting plasmin-digests of lung extracts using an antibody
specific for a neoepitope in fibrin (21). Lung from wild-type mice
subjected to hypoxia displayed a strong band immunoreactive with
anti-fibrin antibody, which was only weakly stained in normoxic
controls (Fig. 4A, lanes 4/5). Consistent with
these results, immunostaining for fibrin in hypoxic lung tissue from
wild-type mice displayed deposits of fibrin immunoreactive material
(Fig. 4C), versus their absence in normoxic lung
(Fig. 4B). In parallel with low levels of tissue factor in
hypoxic PKC
null mice, there was no evidence of fibrin epitopes in
lung tissue harvested from these animals after exposure to oxygen
deprivation by immunoblotting or immunostaining (Fig.
4, panels A
(lane 5) and E; note that
panels A (lane 4) and
D display results in normoxic PKC
null mice). Our data
are consistent with a cause-effect relationship for induction of Egr-1
and tissue factor in hypoxic lung and the appearance of fibrin
deposits, and indicate that PKC
isoforms are upstream of these
events.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 3.
Hypoxia-mediated induction of tissue factor:
effect of PKC deletion. A,
wild-type (+/+) and PKC null ( / ) mice were exposed to hypoxia
(H; 6% oxygen) or normoxia (N) for 4 h and
sacrificed, and total RNA was isolated from the lung and subjected to
Northern analysis (20 µg/lane) with 32P-labeled cDNA
probes for murine tissue factor (TF) and -actin. B-E,
immunostaining using anti-tissue factor IgG in lungs of normoxic
(B) or hypoxic (C) wild-type mice. The arrows in
panel C point to macrophages immunoreactive with
anti-TF IgG. Panels D and E show
immunostaining for tissue factor in lungs from normoxic (D)
and hypoxic (E) PKC null mice. Marker
bar = 2 µm.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 4.
Hypoxia-mediated induction of fibrin
deposition: effect of PKC deletion.
A, wild-type (+/+) and PKC null ( / ) mice were exposed
to hypoxia (H; 6% oxygen) or normoxia (N) for
6 h, sacrificed, and lung protein extract was digested with
plasmin and subjected to SDS-PAGE (7.5%; 0.2 µg of total
protein/lane)/immunoblotting with anti-fibrin antibody.
B-E, immunostaining using anti-fibrin IgG in lungs from
normoxic (B) or hypoxic (C) wild-type mice (+/+).
The arrows in panel C point to
immunoreactive fibrin deposits. Panels D and E
show immunostaining for fibrin in normoxic (D) and hypoxic
(E) PKC null ( / ) mice. Marker
bar = 5 µm.
|
|
Specificity of Suppressed Gene Expression in PKC
Null Mice:
Hypoxia and LPS--
Although PKC
null mice demonstrated inhibition
of Egr-1 and tissue factor gene activation following exposure to
hypoxia, this did not reflect a general suppression of gene expression. For example, systemic infusion of lipopolysaccharide into PKC
null
mice resulted in a strong increase in Egr-1 and tissue factor transcripts in total RNA harvested from lung (Fig. 5, A and
B, respectively, compare lanes 3 and
4). The latter response was comparable to that observed in
wild-type mice (Fig. 5, A and
B, compare lanes 1 and 2).
Also, other pathways regulating the cellular response to hypoxia, such
as HIF-1, remained intact. Up-regulation of the
noninsulin-dependent glucose transporter (GLUT-1) is a well
known feature of the protective response to oxygen deprivation, which
depends, in large part, on HIF-1 (11). Hypoxic PKC
null mice
displayed strong induction of GLUT-1 transcripts in the lung (Fig.
5C, lane 4; lane
3 shows normoxic PKC
null control), which was comparable
to that observed in wild-type animals subjected to the same protocol
(Fig. 5C, lane 2; lane
1 shows the normoxic wild-type control). In terms of
steady-state levels of GLUT-1 transcripts, there was
7.6-fold
increase in wild-type mice and
7.3-fold increase in PKC
null
mice, comparing hypoxia and normoxia (Fig. 5C).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 5.
LPS-mediated induction of Egr-1
(A) and tissue factor (B) and
hypoxia-mediated induction of GLUT1 (C): effect of
PKC deletion. Wild-type (+/+) and PKC
null ( / ) mice were infused with LPS (20 µg) and after either 30 min (A) or 6 h (B) total lung RNA was
isolated and subjected to Northern analysis using
32P-labeled cDNA for Egr-1 (A) or TF
(B). In other experiments (C), mice were exposed
to hypoxia (H; 6% oxygen) or normoxia (N) for
4 h, sacrificed, and total RNA was isolated from the lung, and
subjected to Northern analysis (15 µg/lane) with
32P-labeled cDNA probes for GLUT1 and -actin.
|
|
Macrophage Expression of Tissue Factor in Response to Oxygen
Deprivation: Effect of PKC
Deletion--
One critical site in
hypoxic lung for activation of gene expression in the hypoxia-triggered
Egr-1-tissue factor pathway is the MP (22). It was important to perform
additional experiments to be certain that the observed inhibitory
effect in PKC
null mice reflected events at the level of MPs, rather
than complex intercellular compensatory mechanisms possibly operative
within the PKC
null phenotype (as has been observed with other
knockouts). For example, mice in whom the Interleukin 6 gene had been
deleted displayed high levels of tumor necrosis factor-
, the latter
contributing to the response of these mice to a range of stimuli (38,
39). Resident peritoneal macrophages (also termed MPs) were obtained by
lavage from wild-type and PKC
null mice. Following exposure of MPs
from wild-type mice to hypoxia (pO2
14 torr) for 4 h, induction of tissue factor transcripts was observed by RT-PCR (Fig.
6A, lane 3; lane
2 shows normoxic control). The identity of this amplicon was
confirmed by Southern blotting with a 32P-labeled tissue
factor probe (Fig. 6B, lane 3). In
contrast, similar experiments with resident peritoneal macrophages from PKC
null mice displayed virtually no increase in tissue factor transcripts (Fig. 6, A and
B, lane 7; lane
6 shows the normoxic control). As in our studies using the
intact animal, induction of tissue factor in response to other stimuli,
such as phorbol ester and lipopolysaccharide, remained intact in the
PKC
null mice; both of these stimuli caused an increase in
transcripts in MPs from wild-type (Fig. 6, A and
B, lanes 4 and 5) and
PKC
null mice (Fig. 6, A and B,
lanes 8 and 9).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 6.
Expression of tissue factor by peritoneal
macrophages exposed to LPS, phorbol 12-myristate 13-acetate, or
hypoxia: effect of PKC . Resident
peritoneal macrophages were isolated from age- and strain-matched
wild-type control (+/+, lanes 2-5) and PKC
null mice ( / , lanes 6-9). Cells were exposed
to normoxia (N) or hypoxia (H) for 4 h
(lanes 2 and 3 or lanes
6 and 7). In other experiments, cultures were
maintained in normoxia and exposed to phorbol myristate acetate (50 ng/ml; lanes 4 and 8 labeled
P) for 1 h or to LPS (1 µg/ml; lanes
5 and 9 labeled L) for 6 h.
Following each of these treatments, RNA was isolated, and RT-PCR was
performed with primers for murine tissue factor (TF) or -actin.
Amplicons were visualized by ethidium bromide staining, TF
(A) or -actin (C), or were transferred to
membranes and hybridized with a 32P-labeled cDNA for
murine tissue factor (B). Lane 1 shows
the migration of molecular weight markers (100-base pair DNA ladder;
Promega).
|
|
Hypoxia-induced Expression of Egr-1 in Alveolar Macrophages: Effect
of PKC
Inhibition--
The coagulant properties of alveolar
macrophages are likely to be relevant to the procoagulant environment
of hypoxemic lung. In a previous study with monocyte-like U937 cells,
hypoxia was shown to induce membrane translocation and
autophosphorylation of PKC
II, compared with lack of such changes in
PKC isoforms
and
(22). Furthermore, transient transfection
studies demonstrated that expression of dominant-negative PKC
II
selectively suppressed hypoxia-mediated activation of Egr-1 and tissue
factor transcription (22). In order to determine the applicability of
these results to macrophages in the lung, we turned to a line of
cultured alveolar macrophages (NR8383) and assessed the effect of
hypoxia on induction of Egr-1. The role of PKC
was studied using
LY379196, a selective PKC
inhibitor, although it has a similar
Ki for the
1 and
2 isoforms (36, 37). Exposure
of normoxic macrophages to LY379196 was without effect on Egr-1
expression (data not shown). In the absence of inhibitor, hypoxic
macrophages showed a strong increase in Egr-1 transcripts in hypoxia
(Fig. 7A, lane 2;
10.6-fold increase), compared with cells maintained in normoxia (Fig.
7A, lane
1). However, in the presence of the inhibitor, there was no
apparent increase in Egr-1 transcripts in the hypoxic cells (Fig.
7A, lane 3). The apparent specificity
of the inhibitor for the hypoxia-induced pathway under study was
consistent with the observation that when the alveolar macrophage cell
line was exposed to hypoxia, induction of GLUT-1 mRNA in hypoxic
macrophages was maintained in the presence of LY379196 (Fig.
7B).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 7.
Hypoxia-mediated expression of Egr-1 and
GLUT1: effect of PKC inhibition by
LY379196. A, cultured rat alveolar macrophages (NR8383)
were preincubated with LY379196 (0.2 µM) for 60 min, and
were then incubated under normoxic (N) or hypoxic
(pO2 12-14 torr; H) conditions for 30 min.
Then, total RNA was isolated and Northern analysis was performed (10 µg of RNA/lane) using 32P-labeled cDNA for Egr-1 or
-actin. Note that controls in which LY379196 was incubated with
normoxic NR8383 cells showed no differences in Egr-1 transcripts.
B, cultured alveolar macrophages were treated as in A
(above) except that the incubation time in hypoxia was 4 h, and
Northern blotting was performed with 32P-labeled cDNA
for GLUT1 and -actin.
|
|
 |
DISCUSSION |
Isoforms of PKC have been linked to many physiologic and
pathophysiologic processes (40-44). Recent studies have particularly focussed attention on the
-isoforms because of their potential role
in cardiovascular dysfunction, especially as relates to endothelial cells and cardiac myocytes (45-53). Most studies analyzing PKC
isoforms have relied on inhibitors that show apparent specificity for
I/
II versus other members of the PKC family (44, 45, 54-59). Alternative experimental approaches have employed
overexpression of wild-type PKC
II or inducible expression of a
constitutively active variant in cardiac myocytes (46, 47). Another
means to dissect the contribution of PKC
is use of PKC
null mice. The advantage of this approach is that selective ablation of the PKC
gene would be not be predicted to interfere with other PKC family
members or to impact on downstream targets of PKC
. Of course, the
possibility that compensatory mechanisms are recruited in the absence
of PKC
must be kept in mind, as in any experiment with knockout
mice. Previously described properties of PKC
null mice made them
ideal for our studies, as their growth, reproductive capacity, and
survival are intact (25). Furthermore, although their phenotype remains
to be fully defined, based on their characteristics reported to date
(involving mainly immunologic defects which would not be predicted to
affect phenomena in our study a priori), it appears that
multiple physiologic responses, such as induction of GLUT1 consequent
to hypoxia and expression of tissue factor following LPS, remain intact.
Studies reported herein using PKC
null mice delineate a central role
for PKC
in hypoxia-mediated induction of Egr-1 transcription, which
leads to increased expression of tissue factor. Our previous studies
with cultured monocyte-like cell lines demonstrated that oxygen
deprivation triggered PKC
II activation within minutes, and was
followed by a pathway including Raf, mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase, and ERK1/2 (22).
Subsequent ERK1/2-induced activation of elk-1, resulting in formation
of a complex with serum response factor, promotes transcription of
Egr-1, and leads directly to tissue factor transcription. The current
results in PKC
null mice confirm the broad outlines of this pathway
in vivo, and indicate a cause-effect relationship between
PKC
activation in hypoxemic lung and subsequent events leading to
tissue factor induction: 1) enhanced expression of Egr-1 and tissue
factor observed in response to oxygen deprivation in wild-type mice was
not observed to any appreciable extent in PKC
null animals; 2)
hypoxia-mediated activation of ERK1/2, key contributors to the pathway
linking PKC
activation to up-regulation of Egr-1 transcription, was
also not seen in PKC
null mice; and 3) levels of tissue factor
antigen remained low and pulmonary vascular fibrin deposition was not
observed in hypoxic PKC
null mice. These data provide strong support
for a pathway in which activation of PKC
triggers events leading to
accumulation of fibrin in pulmonary vasculature. This response occurs
rapidly and could potentially have long term effects on vascular
properties by several mechanisms; deposited fibrin could block blood
flow and trigger vascular remodeling directly, thrombin formed within the vessel could activate thrombin receptors on cells within the vessel
wall (60), and other target genes of Egr-1 and PKC
could be expressed.
The biologic significance of the PKC
-Egr-1-tissue factor pathway
induced by hypoxia will require considerably more study to delineate.
However, it is clear that these hypoxia-mediated events can be
differentiated from HIF-1-induced responses. Whereas hypoxia-induced
up-regulation of Egr-1 and tissue factor was strongly suppressed in
PKC
null mice, oxygen deprivation led to comparable induction of
GLUT-1 (which is largely due to HIF-1) (11) in PKC
null and
wild-type mice. This is consistent with our previous observation that a
cultured hepatoma line unable to form active HIF-1, due to deficient
ARNT/HIF-1
function, demonstrated comparable induction of Egr-1
transcripts, versus that in wild-type controls, when exposed
to hypoxia (22). Furthermore, expression of tissue factor in response
to other stimuli, such as phorbol ester and LPS, also remained intact
in PKC
null mice. In this context, the adaptive advantage of a
pathway causing induction of local vascular fibrin formation remains
uncertain; though it could allow sequestration of hypoxemic areas from
nonischemic tissues, the possibility that subsequent obstructive
thrombus formation might prevent blood flow leading to necrosis also
exists. Future studies examining the range of responses triggered by
PKC
and Egr-1 activation in hypoxemic tissues will be required to
appreciate the impact of these events on the vascular adaptation to
hypoxemia. Another important issue concerns the specificity of this
pathway for different cells and in different tissues. Our studies in
hypoxemic lung have shown strong up-regulation of Egr-1 and tissue
factor at the antigen level in smooth muscle cells and MPs. However, in view of the presence of Egr-1 in virtually every cell, and the similar
potential of a wide range of cells to express tissue factor, it will be
essential to know why certain cells are especially susceptible to
hypoxia-induced responses in this pathway. Nonetheless, the
contribution of the current work is to firmly establish that PKC
has
an integral role in an hypoxia-induced pathway leading to activation of
MAP kinases, and transcription of Egr-1 and tissue factor. These
observations form a strong foundation for future studies to further
analyze in detail mechanisms underlying this pathway in
vitro and physiologic consequences for such effector mechanisms
in vivo.
 |
FOOTNOTES |
*
This work was supported by United States Public Health
Service Grants HL42507, HL63967, HL48872, and PERC, and by the Surgical Research Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Dept. of Surgery, P&S
11-420, College of Physicians & Surgeons of Columbia University, 630 W. 168th St., New York, NY 10032. Tel.: 212-305-6030; Fax: 212-305-5337;
E-mail: sy18@columbia.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
HIF-1, hypoxia-inducible factor-1;
ORP, oxygen-regulated protein;
GRP, glucose-regulated protein;
PKC, protein kinase C;
RT, reverse
transcription;
PCR, polymerase chain reaction;
ER, endoplasmic
reticulum;
PAGE, polyacrylamide gel electrophoresis;
LPS, lipopolysaccharide;
MAPK, mitogen-activated protein kinase;
MP, mononuclear phagocyte;
Egr-1, Early Growth Response-1;
ERK, extracellular signal-regulated kinase;
TF, tissue factor.
 |
REFERENCES |
| 1.
|
Guillemin, K.,
and Krasnow, M.
(1997)
Cell
89,
9-12[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Semenza, G.
(1996)
Trends Cardiovasc. Med.
6,
151-157
|
| 3.
|
Wood, S. M.,
Gleadle, J.,
Pugh, C.,
Hankinson, O.,
and Ratcliffe, P.
(1996)
J. Biol. Chem.
271,
15117-15123[Abstract/Free Full Text]
|
| 4.
|
Pinsky, D. J.,
Naka, Y.,
Liao, H.,
Oz, M. C.,
Wagner, D. D.,
Tanya, N. M.,
Johnson, R. C.,
Heath, M.,
Lawson, C. A.,
and Stern, D. M.
(1996)
J. Clin. Invest.
97,
493-500[Medline]
[Order article via Infotrieve]
|
| 5.
|
Muller, J.,
Krauss, B.,
Kaltschmidt, C.,
Baeuerle, P.,
and Rupec, R.
(1997)
J. Biol. Chem.
272,
23435-23439[Abstract/Free Full Text]
|
| 6.
|
Yan, S.-F.,
Zou, Y.-S.,
Gao, Y.,
Zhai, C.,
Mackman, N.,
Lee, S.,
Milbrandt, J.,
Pinsky, D.,
Kisiel, W.,
and Stern, D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8298-8303[Abstract/Free Full Text]
|
| 7.
|
Bunn, H.,
and Poyton, R.
(1996)
Physiol. Rev.
76,
839-885[Abstract/Free Full Text]
|
| 8.
|
Heacock, C.,
and Sutherland, R.
(1986)
Int. J. Radiat. Oncol. Biol. Phys.
12,
1287-1290[Medline]
[Order article via Infotrieve]
|
| 9.
|
Michiels, C.,
Arnould, T.,
Knott, I.,
Dieu, M.,
and Remacle, J.
(1993)
Am. J. Physiol.
264,
C866-C874[Abstract/Free Full Text]
|
| 10.
|
Zhu, H.,
and Bunn, H. F.
(1999)
Respir. Physiol.
115,
239-247[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Iyer, N.,
Kotche, L.,
Agani, F.,
Leung, S.,
Laughner, E.,
Wenger, R.,
Gassmann, M.,
Gearhart, J.,
Lawler, A., Yu, A.,
and Semenza, G.
(1998)
Genes Dev.
12,
149-162[Abstract/Free Full Text]
|
| 12.
|
Semenza, G.,
Roth, P.,
Fang, H.-M.,
and Wang, G.
(1994)
J. Biol. Chem.
269,
23757-23763[Abstract/Free Full Text]
|
| 13.
|
Shweiki, D.,
Itin, A.,
Soffer, D.,
and Keshet, E.
(1992)
Nature
359,
843-845[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Carmeliet, P.,
Ferreira, V.,
Breier, G.,
Pollefey, S.,
Kieckens, L.,
Gertsenstein, M.,
Fahrig, M.,
Vandenhoeck, A.,
Harpal, K.,
Eberhardt, C.,
Declercq, C.,
Pawling, J.,
Moons, L.,
Collen, D.,
Risau, W.,
and Nagy, A.
(1996)
Nature
380,
435-439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Ferrara, N.,
Carver-Moore, K.,
Chen, H.,
Dowd, M.,
Lu, L.,
O'Shea, K.,
Powell-Braxton, L.,
Hillan, K.,
and Moore, M.
(1996)
Nature
380,
439-442[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kotch, L.,
Iyer, N.,
Laughner, E.,
and Semenza, G.
(1999)
Dev. Biol.
209,
254-267[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Carmeliet, P.,
Dor, Y.,
Herbert, J.,
Fukumura, D.,
Brusselmans, K.,
Dewerchin, M.,
Neeman, M.,
Bono, F.,
Abramovitch, R.,
Maxwell, P.,
Koch, C.,
Ratcliffe, P.,
Moons, L.,
Jain, R.,
Collen, D.,
and Keshert, E.
(1998)
Nature
394,
485-490[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Wynn, R.,
David, J.,
Cox, R.,
and Chuang, D.
(1994)
J. Lab. Clin. Med.
124,
31-36[Medline]
[Order article via Infotrieve]
|
| 19.
|
Kuwabara, K.,
Matsumoto, M.,
Ikeda, J.,
Hori, O.,
Ogawa, S.,
Maeda, Y.,
Kitagawa, K.,
Imuta, N.,
Kinoshita, T.,
Stern, D.,
Yanagi, H.,
and Kamada, T.
(1996)
J. Biol. Chem.
271,
5025-5032[Abstract/Free Full Text]
|
| 20.
|
Ozawa, K.,
Kuwabara, K.,
Tamatani, M.,
Takatsuhi, K.,
Tsukamoto, Y.,
Kaneda, S.,
Yanagi, H.,
Stern, D.,
Eguchi, Y.,
Tsujimoto, Y.,
Ogawa, S.,
and Tohyama, M.
(1999)
J. Biol. Chem.
274,
6397-6404[Abstract/Free Full Text]
|
| 21.
|
Lawson, C.,
Yan, S.-D.,
Yan, S.-F.,
Liao, H.,
Zhou, Y.-S.,
Sobel, J.,
Kisiel, W.,
Stern, D.,
and Pinsky, D.
(1997)
J. Clin. Invest.
99,
1729-1738[Medline]
[Order article via Infotrieve]
|
| 22.
|
Yan, S.-D.,
Lu, J.,
Zou, Y.-S.,
Soh-Won, J.,
Cohen, D.,
Buttrick, P.,
Cooper, D.,
Steinberg, S.,
Mackman, N.,
Pinsky, D.,
and Stern, D.
(1999)
J. Biol. Chem.
274,
15030-15040[Abstract/Free Full Text]
|
| 23.
|
Geerts, W.,
Code, K.,
Jay, R.,
Chen, E.,
and Szalai, J.
(1994)
N. Engl. J. Med.
331,
1601-1606[Abstract/Free Full Text]
|
| 24.
|
Anderson, F.,
Wheeler, H.,
Goldberg, R.,
Hosmer, D.,
Patwardhan, N.,
Jovanovic, B.,
Forcier, A.,
and Dalen, J.
(1991)
Arch. Intern. Med.
151,
933-938[Abstract]
|
| 25.
|
Leitges, M.,
Schmedt, C.,
Guinamard, R.,
Davoust, J.,
Schaal, S.,
Stabel, S.,
and Tarakhovsky, A.
(1996)
Science
273,
788-791[Abstract]
|
| 26.
|
Lemaire, P.,
Vesque, C.,
Schmitt, J.,
Stunnenberg, H.,
Frank, R.,
and Charnay, P.
(1990)
Mol. Cell Biol.
10,
3456-3467[Abstract/Free Full Text]
|
| 27.
|
Loike, J.,
Cao, L.,
Brett, J.,
Ogawa, S.,
Silverstein, S.,
and Stern, D.
(1992)
Am. J. Physiol.
263,
C326-C333[Abstract/Free Full Text]
|
| 28.
|
Johnson, D.,
Gautsch, J.,
Sportsman, J.,
and Elder, J.
(1984)
Gene Anal. Tech.
1,
3-8
|
| 29.
|
Seger, R.,
and Krebs, E.
(1995)
FASEB J.
9,
726-732[Abstract]
|
| 30.
|
Cano, E.,
and Mahadevan, L.
(1995)
Trends Biochem. Sci.
20,
117-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Francis, C.,
Marder, V.,
and Martin, S.
(1980)
Blood
56,
456-464[Abstract/Free Full Text]
|
| 32.
|
Lahiri, B.,
Koehn, J.,
Canfield, R.,
Birken, S.,
and Lewis, J.
(1981)
Thromb. Res.
23,
103-112[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Dignam, J.,
Lebovitz, R.,
and Roeder, R.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 34.
|
Yan, S.-F.,
Tritto, I.,
Pinsky, D. J.,
Liao, H.,
May, L.,
and Stern, D. M.
(1995)
J. Biol. Chem.
270,
11463-11471[Abstract/Free Full Text]
|
| 35.
|
McCarron, R.,
Goroff, D.,
Luhr, J.,
Murphy, M.,
and Herscowitz, H.
(1984)
Methods Enzymol.
108,
274-284[Medline]
[Order article via Infotrieve]
|
| 36.
|
Braiman, L.,
Sheffi-Friedman, L.,
Bak, A.,
Tennenbaum, T.,
and Sampson, S.
(1999)
Diabetes
48,
1922-1929[Abstract]
|
| 37.
|
Bandyopadhyay, G.,
Standaert, M.,
Galloway, L.,
Moscat, J.,
and Farese, R.
(1997)
Endocrinology
138,
4721-4731[Abstract/Free Full Text]
|
| 38.
|
Fattori, E.,
Cappelletti, M.,
Costa, P.,
Sellitto, C.,
Cantoni, L.,
Carelli, M.,
Faggioni, R.,
Fantuzzi, G.,
Ghezzi, P.,
and Poli, V.
(1994)
J. Exp. Med.
180,
1243-1250[Abstract/Free Full Text]
|
| 39.
|
DiSanto, E.,
Alonzi, T.,
Poli, V.,
Fattori, E.,
Toniatti, C.,
Sironi, M.,
Ricciardi-Castagnoli, P.,
and Ghezzi, P.
(1997)
Cyto
9,
300-306
|
| 40.
|
Simkhovich, B.,
Przyklenk, K.,
and Kloner, R.
(1998)
Cardiovasc. Res.
40,
9-22[Abstract/Free Full Text]
|
| 41.
|
Morgan, K.,
and Leinweber, B.
(1998)
Acta Physiol. Scand.
164,
495-505[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Kanashiro, C.,
and Khalil, R.
(1998)
Clin. Exp. Pharmacol. Physiol.
25,
974-985[Medline]
[Order article via Infotrieve]
|
| 43.
|
Cain, B.,
Meldru, D.,
and Harken, A.
(1999)
J. Surg. Res.
81,
249-259[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Goekjian, P.,
and Jirousek, M.
(1999)
Curr. Med. Chem.
6,
877-903[Medline]
[Order article via Infotrieve]
|
| 45.
|
Koya, D.,
and King, G.
(1998)
Diabetes
47,
859-866[Abstract]
|
| 46.
|
Bowman, J.,
Steinberg, S.,
Jiang, T.,
Geenen, D.,
Fishman, G.,
and Buttrick, P.
(1997)
J. Clin. Invest.
100,
2189-2195[Medline]
[Order article via Infotrieve]
|
| 47.
|
Wakasaki, H.,
Koya, D.,
Schoen, F.,
Jirousek, M.,
Ways, D. K.,
Hoit, B.,
Walsh, R.,
and King, G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
9320-9325[Abstract/Free Full Text]
|
| 48.
|
Ladilov, Y.,
Balser, C.,
and Piper, H.
(1998)
Circ. Res.
82,
451-457[Abstract/Free Full Text]
|
| 49.
|
Numaguchi, K.,
Shimokawa, H.,
Nakaike, R.,
Egashira, K.,
and Takeshita, A.
(1996)
Am. J. Physiol.
270,
H1634-H1639[Abstract/Free Full Text]
|
| 50.
|
Lasley, R.,
Noble, M.,
and Mentzer, R.
(1997)
J. Mol. Cell. Cardiol.
29,
3345-3356[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Qiu, Y.,
Ping, P.,
Manchikalapudi, S.,
Rizvi, A.,
Zhang, J.,
Takano, H.,
Wu, W.,
Teschner, S.,
and Bolli, R.
(1998)
J. Clin. Invest.
101,
2182-2198[Medline]
[Order article via Infotrieve]
|
| 52.
|
Speechly-Dick, M.,
Mocanu, M.,
and Yellon, D.
(1994)
Circ. Res.
75,
586-590[Abstract/Free Full Text]
|
| 53.
|
Li, Y.,
and Kloner, R.
(1995)
Am. J. Physiol.
268,
H426-H431[Abstract/Free Full Text]
|
| 54.
|
Danis, R.,
Bingaman, D.,
Jirousek, M.,
and Yang, Y.
(1998)
Invest. Ophthalmol. Vis. Sci.
39,
171-179[Abstract/Free Full Text]
|
| 55.
|
Rabbi, M.-F.,
al-Harthi, L.,
Saifuddin, M.,
and Roebuck, K.
(1998)
Virology
245,
257-269[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Hata, Y.,
Rook, S.,
and Aiello, L.
(1999)
Diabetes
48,
1145-1155[Abstract]
|
| 57.
|
Efendiev, R.,
Bertorello, A.,
and Pedemonte, C.
(1999)
FEBS Lett.
456,
45-48[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Nakamura, J.,
Kato, K.,
Hamada, Y.,
Nakayama, M.,
Chaya, S.,
Nakashima, E.,
Narue, K.,
Kasuya, Y.,
Mizubayashi, T.,
Miwa, K.,
Yasuda, Y.,
Kamiya, H.,
Ienaga, K.,
Sakakibara, F.,
Koh, N.,
and Hotta, N.
(1999)
Diabetes
48,
2090-2095[Abstract]
|
| 59.
|
Li, J.,
Qu, W.,
and Schmidt, A.-M.
(1998)
J. Biol. Chem.
273,
30870-30878[Abstract/Free Full Text]
|
| 60.
|
Coughlin, S. R.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
11023-11027[Abstract/Free Full Text]
|
Copyright © 200